Antengene Corporation Limited (SEHK: 6996.HK), a China-based biopharmaceutical company, announced on Thursday that it has named Dr Bo Shan, PhD as its new chief scientific officer effective 26 March 2021.

In the new role, Dr Shan will head the strategic planning and execution for drug discovery, early development, and CMC, and will directly report to Dr Jay Mei, Antengene founder, chairman and CEO.

Dr Shan has around 20 years of global pharmaceutical industry experience and has headed interdisciplinary teams to deliver multiple IND and NDA programs throughout his career. He has served as corporate vice president at Antengene.